Masimo Receives Sustainability Seal of Approval from Practice Greenhealth
Masimo Becomes First Pulse Oximetry Manufacturer to be Recognized with Coveted “Greenhealth Approved” SealIRVINE, Calif. & RESTON, Va.--(BUSINESS WIRE)--Masimo (NASDAQ:...
Brain
CNS Pharmaceuticals to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21st at 1:40 PM ETHOUSTON, TX / ACCESSWIRE / May 20, 2024 /...
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without...
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May...
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company...
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Masimo and Denon Introduce White PerL™ and PerL Pro™ Earbuds, Redefining Style and Customization in Personalized Audio
The only earbuds on the market that analyze your hearing profile to generate truly custom sound made just for youIRVINE,...
FSD Pharma Provides Update on Celly Nu’s New Packaging for unbuzzd(TM)
TORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update by way...
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing...
Glioblastoma Foundation(R) Announces the Establishment of Groundbreaking Genomic Testing & Research Laboratory
DURHAM, NC / ACCESSWIRE / May 15, 2024 / The Glioblastoma Foundation announced today the establishment of a pioneering Genomic...
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
Eli Lilly’s and AstraZeneca’s Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops...
Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting...
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic...
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data...
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to...
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected...